[{"id":"fe033f7e-24b3-4288-bdd8-92b0259dd61d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010005","created_at":"2021-08-18T15:53:40.772Z","updated_at":"2025-02-25T15:27:02.226Z","phase":"Phase 1","brief_title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","source_id_and_acronym":"NCT05010005","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Copiktra (duvelisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-10"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"5721b478-7256-41e9-bdb4-f8b5fa921a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05418088","created_at":"2022-06-14T21:56:15.500Z","updated_at":"2025-02-25T17:01:57.164Z","phase":"Phase 1","brief_title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05418088","lead_sponsor":"Sumithira Vasu","biomarkers":" CD20 • CD19 • CD22","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-02-03"},{"id":"b3cbc60c-b805-4974-b2a9-560e9eb38edd","acronym":"NCI-2018-00315","url":"https://clinicaltrials.gov/study/NCT03479268","created_at":"2021-01-18T17:08:37.744Z","updated_at":"2025-02-25T17:35:59.375Z","phase":"Phase 1","brief_title":"Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03479268 - NCI-2018-00315","lead_sponsor":"City of Hope Medical Center","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/22/2018","start_date":" 03/22/2018","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2025-01-29"},{"id":"cb1a79b5-e061-4b3c-834a-601d77043b7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512497","created_at":"2021-01-18T12:08:16.611Z","updated_at":"2025-02-25T14:35:44.470Z","phase":"Phase 1","brief_title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT02512497","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-10-29"},{"id":"d7ed8a2f-8937-4cbd-aa4d-ea29935f9c24","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195633","created_at":"2021-01-18T20:26:55.926Z","updated_at":"2024-07-02T16:35:01.612Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","source_id_and_acronym":"NCT04195633","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-23"},{"id":"cb8bf821-dc6c-45cb-b69e-e0395df8d0ca","acronym":"BAH246","url":"https://clinicaltrials.gov/study/NCT06420076","created_at":"2024-05-25T04:25:14.770Z","updated_at":"2024-07-02T16:35:02.887Z","phase":"Phase 1/2","brief_title":"Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells","source_id_and_acronym":"NCT06420076 - BAH246","lead_sponsor":"Essen Biotech","biomarkers":" CD5 • CD7","pipe":"","alterations":" ","tags":["CD5 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/10/2024","start_date":" 09/10/2024","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 12/28/2026","study_completion_date":" 12/28/2026","last_update_posted":"2024-05-17"},{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"c0c1d749-be49-44e4-a22c-cd71bfbd84c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04191187","created_at":"2021-01-18T20:25:39.923Z","updated_at":"2024-07-02T16:35:06.141Z","phase":"Phase 2","brief_title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","source_id_and_acronym":"NCT04191187","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 02/11/2024","primary_completion_date":" 02/11/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"500cdb1b-cc26-4d01-947d-9f667ab8c48a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04771572","created_at":"2021-02-25T15:52:22.502Z","updated_at":"2024-07-02T16:35:07.720Z","phase":"Phase 1","brief_title":"Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.","source_id_and_acronym":"NCT04771572","lead_sponsor":"Newave Pharmaceutical Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LP-118"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-04-24"},{"id":"acdeafe3-7008-41f0-8f96-f453b266a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01588015","created_at":"2021-01-18T06:46:27.904Z","updated_at":"2024-07-02T16:35:12.025Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT01588015","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" PD-1 expression","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/29/2012","start_date":" 10/29/2012","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2024-04-02"},{"id":"a660173e-535e-4057-9814-041d32dd6698","acronym":"","url":"https://clinicaltrials.gov/study/NCT00719888","created_at":"2021-01-18T02:42:00.338Z","updated_at":"2024-07-02T16:35:24.418Z","phase":"Phase 2","brief_title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","source_id_and_acronym":"NCT00719888","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 11/18/2005","start_date":" 11/18/2005","primary_txt":" Primary completion: 12/22/2023","primary_completion_date":" 12/22/2023","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2024-01-05"},{"id":"fcd0e2ae-efb5-4c64-b0ac-7d867e26098a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05978141","created_at":"2023-08-07T14:08:44.907Z","updated_at":"2024-07-02T16:35:26.304Z","phase":"","brief_title":"A Registry for People With T-cell Lymphoma","source_id_and_acronym":"NCT05978141","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ALK • CD8","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/27/2030","primary_completion_date":" 07/27/2030","study_txt":" Completion: 07/27/2030","study_completion_date":" 07/27/2030","last_update_posted":"2023-12-13"},{"id":"20bb3a60-35cb-4903-9d63-a1cf0ddca8cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01962636","created_at":"2021-01-18T08:55:07.216Z","updated_at":"2024-07-02T16:35:30.509Z","phase":"","brief_title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","source_id_and_acronym":"NCT01962636","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A • IKZF1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-11-03"},{"id":"6874df97-e833-4a9e-bd15-5cc442d40050","acronym":"","url":"https://clinicaltrials.gov/study/NCT05377827","created_at":"2022-05-17T11:53:47.550Z","updated_at":"2024-07-02T16:35:33.726Z","phase":"Phase 1","brief_title":"Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies","source_id_and_acronym":"NCT05377827","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e soficabtagene geleucel (WU CART 007)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-10-12"},{"id":"147be330-c08c-4ed4-9d27-7e0355b313e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02661035","created_at":"2021-01-18T12:57:57.203Z","updated_at":"2024-07-02T16:35:36.183Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC for Hematological Diseases","source_id_and_acronym":"NCT02661035","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • KMT2A • IKZF1 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A • IKZF1 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 03/09/2017","start_date":" 03/09/2017","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 05/29/2023","study_completion_date":" 05/29/2023","last_update_posted":"2023-09-21"},{"id":"3bafa6d0-29f9-4e0c-8308-7ec0cbbe6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03010358","created_at":"2021-01-18T14:49:09.492Z","updated_at":"2024-07-02T16:35:40.703Z","phase":"Phase 1/2","brief_title":"Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03010358","lead_sponsor":"Alexey Danilov, MD","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • entospletinib (GS-9973)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 04/29/2021","primary_completion_date":" 04/29/2021","study_txt":" Completion: 04/29/2021","study_completion_date":" 04/29/2021","last_update_posted":"2023-08-08"},{"id":"f8bfbabd-a095-4dce-9f97-609ef1a78c91","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225584","created_at":"2022-11-09T15:57:03.257Z","updated_at":"2024-07-02T16:35:41.087Z","phase":"Phase 1","brief_title":"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors","source_id_and_acronym":"NCT05225584","lead_sponsor":"Kymera Therapeutics, Inc.","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KT-333"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/19/2022","start_date":" 05/19/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-08-03"},{"id":"e1c7ba24-44af-4b89-9a62-1500c297696f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02722668","created_at":"2021-01-18T13:19:16.731Z","updated_at":"2024-07-02T16:35:54.803Z","phase":"Phase 2","brief_title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","source_id_and_acronym":"NCT02722668","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2023-02-24"},{"id":"a007902a-0a7f-41d6-85c9-d3d6c51f4f3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689453","created_at":"2021-01-18T13:07:06.175Z","updated_at":"2024-07-02T16:36:11.245Z","phase":"Phase 1","brief_title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","source_id_and_acronym":"NCT02689453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/19/2017","start_date":" 01/19/2017","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2022-04-29"},{"id":"8ff074b0-3b16-48a8-96f5-5fc1ed9fb6cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00546793","created_at":"2021-01-18T01:59:26.165Z","updated_at":"2024-07-02T16:36:26.283Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL","source_id_and_acronym":"NCT00546793","lead_sponsor":"Gilead Sciences","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Veltucyn (veltuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2021-08-16"},{"id":"ee9a82ff-9d07-40c0-aa40-35c972c3dfe2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00309842","created_at":"2021-01-18T01:03:54.232Z","updated_at":"2024-07-02T16:36:41.141Z","phase":"Phase 2","brief_title":"Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases","source_id_and_acronym":"NCT00309842","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A • IKZF1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 07/28/2005","start_date":" 07/28/2005","primary_txt":" Primary completion: 07/29/2019","primary_completion_date":" 07/29/2019","study_txt":" Completion: 11/22/2019","study_completion_date":" 11/22/2019","last_update_posted":"2020-09-10"},{"id":"99bdb023-9b6e-4c98-a74c-8967a6b4bdbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03097770","created_at":"2021-01-18T15:15:47.403Z","updated_at":"2024-07-02T16:36:41.414Z","phase":"Phase 1/2","brief_title":"Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20","source_id_and_acronym":"NCT03097770","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 05/10/2019","primary_completion_date":" 05/10/2019","study_txt":" Completion: 01/31/2020","study_completion_date":" 01/31/2020","last_update_posted":"2020-09-02"}]